Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 698-700 , November 2007

Renal Function, Diuretic Action, and Heart Failure: A Therapeutic Conundrum

  • Domenic Sica, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Domenic A. Sica, MD, Professor of Medicine and Pharmacology Chairman, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University Health System, Richmond, VA 23298-0160.

References 

  1. Smith GL, Shlipak MG, Havranek EP, et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation. 2005;111:1270–1277
  2. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–1996
  3. de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27:569–581
  4. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure. J Card Fail. 2007;13:599–608
  5. Arimoto T, Takeishi Y, Niizeki T, et al. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail. 2005;11:595–601
  6. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210
  7. Dittrich H, Gupta DK, Hack TC, et al. The effect of KW-3092, an adenosine A1 receptor antagonist in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007;13:609–617
  8. Kriz W. Adenosine and ATP: traffic regulators in the kidney. J Clin Invest. 2004;114:611–613
  9. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901–940
  10. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229–249
  11. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  12. Colleta L, Tin P, Loh A, et al. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur J Heart Fail. 2007;8:547–549
  13. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551–1560
  14. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist. 2005;11:25–36

PII: S1071-9164(07)01076-7

doi: 10.1016/j.cardfail.2007.10.001

Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 698-700 , November 2007

Article Tools